Clinical Trial Update: Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney Disease [Phase 2]

View source ↗

Summary

Phase 2 trial investigating BMS-813160 for reducing protein loss in urine in patients with diabetic kidney disease was terminated; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Kidney Disease

Drugs mentioned

• BMS-813160

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Diabetic Kidney Disease | Phase 2 | Status: TERMINATED | Results posted: 2019-06-25